Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LHCGR | P22888 | 8/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | FSHR | P23945 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | RORB | Q92753 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2132337 | 0.92 | LHCGR (0.60) | LHCGRTSHRFSHRBRAFPDE4A | |
| SCHEMBL5025967 | 0.89 | LHCGR (0.62) | LHCGRTSHRMAPTKMT2AMEN1 | |
| SCHEMBL6216455 | 0.88 | LHCGR (0.59) | LHCGRTSHRMAPTKMT2AMEN1 | |
| SCHEMBL6215212 | 0.87 | MAPT (0.55) | LHCGRTSHRMAPTKMT2AMEN1 | |
| SCHEMBL4419261 | 0.86 | LHCGR (0.77) | LHCGRTSHRMAPTKMT2AMEN1 | |
| SCHEMBL2131332 | 0.86 | LHCGR (0.61) | LHCGRTSHRMAPTKMT2AMEN1 | |
| SCHEMBL4899220 | 0.86 | BRAF (0.61) | LHCGRTSHRMAPTKMT2AMEN1 | |
| SCHEMBL14285233 | 0.84 | LHCGR (0.56) | LHCGRTSHRMAPTKMT2AMEN1 | |
| SCHEMBL4908873 | 0.82 | LHCGR (0.55) | LHCGRTSHRMAPTKMT2AMEN1 | |
| SCHEMBL4421145 | 0.81 | BRAF (0.62) | LHCGRTSHRFSHRBRAFPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445916-A1 | ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS | Merck Patent GmbH (DE) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101095-A1 | ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-04-26 | — | — | US | disclosed |
| US-20120101095-A1 | ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-04-26 | — | — | US | disclosed |
| US-20120101095-A1 | ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-04-26 | — | — | US | disclosed |
| WO-2010149257-A1 | ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS | MERCK PATENT GMBH (DE) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101095-A1 | ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS | TGFBR1, TGFBR2, TGFB1 | LHCGR 1781/4885TSHR 133/4885MAPT 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.